Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- or third-line treatment of patients with metastatic breast cancer
2009-018025-73Phase 2Completed
- Sponsor
- GMIHO mbH
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sorafenib in breast cancer (2 arms), sponsored by GMIHO mbH. Primary endpoint: Progression-free survival. Started Mar 2010; status: completed.
02
Drugs
sorafenib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-018025-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018025-73.